GlassScriptPhysician profile
Taylor Grace Halter
NPI 1457906653
$3,156.00
in general payments reported to CMS, 2019-2025
31 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $301 · 2022: $127 · 2024: $1,136 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,445 · Education: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,444.84 |
| Education | $282.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $473.82 | 2024-2025 | Tremfya |
| Abbvie INC. | $405.13 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $319.12 | 2024-2025 | Sotyktu |
| Novo Nordisk INC | $178.33 | 2021-2022 | |
| Ucb, INC. | $168.81 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $152.24 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $144.52 | 2024-2025 | Dupixent |
| Amgen INC. | $133.03 | 2022-2025 | Otezla, Otezla |
| Lilly USA, LLC | $123.46 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $113.74 | 2024-2025 | Adbry, Anzupgo |
| Janssen Pharmaceuticals, INC | $112.79 | 2024 | Tremfya |
| Incyte Corporation | $111.63 | 2024-2025 | Opzelura |
| Genzyme Corporation | $110.11 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Arcutis Biotherapeutics, INC. | $74.77 | 2025 | Zoryve |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $57.27 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.28 | 2021-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.27 | 2024 | Cabtreo |
| Pfizer INC. | $34.86 | 2024 | |
| Dexcom, INC. | $33.44 | 2022 | |
| Organon LLC | $29.16 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $28.54 | 2021 | |
| Glaxosmithkline, LLC. | $25.46 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.37 | 2022 | |
| Sun Pharmaceutical Industries INC. | $25.30 | 2025 | |
| Genentech USA, INC. | $19.10 | 2021 | |
| Journey Medical Corporation | $17.57 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $16.55 | 2024 | Simlandi |
| Sandoz INC. | $15.41 | 2024 | Hyrimoz |
| Pacira Therapeutics, INC. | $14.54 | 2021 | |
| Mayne Pharma Commercial LLC | $10.39 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Halter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.